The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Open accessAbstract
SummaryAlzheimer’s disease (AD) is characterized by the deposition of β-amyloid within the brain parenchyma and is accompanied by the impairment of neuronal metabolism and function, leading to extensive neuronal loss. The disease involves the perturbation of synaptic function, energy, and lipid metabolism. The development of amyloid plaques results in the induction of a microglial-mediated inflammatory response. The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor whose biological actions are to regulate glucose and lipid metabolism and suppress inflammatory gene expression. Thus, agonists of this receptor represent an attractive therapeutic target for AD. There is now an extensive body of evidence that has demonstrated the efficacy of PPARγ agonists in ameliorating disease-related pathology and improved learning and memory in animal models of AD. Recent clinical trials of the PPARy agonist rosiglitazone have shown significant improvement in memory and cognition in AD patients. Thus, PPARγ represents an important new therapeutic target in treating AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedMootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Recently, however, rosiglitazone usage was found to be associated with an increased risk for cardiovascular side effects.(31) In contrast, pioglitazone has been found to be cardioprotective.”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80611-x · Cited by 4,139
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 2×
“each member functions to regulate a unique subset of genes responsible for lipid and energy metabolism.(3) The”
BackgroundCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Nuclear Hormone Receptors and Gene Expression
Aranda, A., & Pascual, A. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1269 · Cited by 1,570
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,254
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.049 · Cited by 1,015
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Emerging roles of PPARS in inflammation and immunity
Daynes, R. A., & Jones, D. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri912 · Cited by 919
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884
Differential Effects of Apolipoproteins E3 and E4 on Neuronal Growth in Vitro
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R. E. (1994) · Science · doi:10.1126/science.8171342 · Cited by 795
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Glucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C. V., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0978fje · Cited by 630
Small, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
Watson, G. S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 597
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Self-citationCraft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524
Colangelo, V., Schurr, J., Ball, M. J., Pelaez, R. P., Bazan, N. G., & Lukiw, W. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10351 · Cited by 517
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Self-citationPioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo
Bogacka, I., Xie, H., Bray, G. A., & Smith, S. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1392 · Cited by 467
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Inflammation and Alzheimer's disease pathogenesis
Rogers, J., Webster, S., Lue, L.-F., Brachova, L., Harold Civin, W., Emmerling, M., Shivers, B., Walker, D., & McGeer, P. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00115-7 · Cited by 442
Kuusisto, J., Koivisto, K., Mykkänen, L., Helkala, E.-L., Vanhanen, M., Hänninen, T., Kervinen, K., Kesäniemi, Y. A., Riekkinen, P. J., & Laakso, M. (1997) · BMJ · doi:10.1136/bmj.315.7115.1045 · Cited by 429
Haan, M. N., Mungas, D. M., Gonzalez, H. M., Ortiz, T. A., Acharya, A., & Jagust, W. J. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51054.x · Cited by 420
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33622 · Cited by 407 · cited 1×
“Conversely, overexpression of human Abca1 in mice resulted in reduced A levels and plaque burden.(96) Importantly, the expression of the Abca1 gene is transcriptionally regulated by the nuclear receptors, liver X receptors (LXRs), PPAR , and RXR.”
BackgroundDiabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study
Xu, W. L., Qiu, C. X., Wahlin, A., Winblad, B., & Fratiglioni, L. (2004) · Neurology · doi:10.1212/01.wnl.0000140291.86406.d1 · Cited by 407
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500579102 · Cited by 401
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385
Li, M., Pascual, G., & Glass, C. K. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.13.4699-4707.2000 · Cited by 377
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Self-citationRole of mitochondrial dysfunction in Alzheimer's disease
Castellani, R., Hirai, K., Aliev, G., Drew, K. L., Nunomura, A., Takeda, A., Cash, A. D., Obrenovich, M. E., Perry, G., & Smith, M. A. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10389 · Cited by 364
Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors
Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., Vinters, H. V., & Tontonoz, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701096104 · Cited by 358
Self-citationSastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., van Leuven, F., & Heneka, M. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 357
Self-citationLack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350
Holtzman, D. M., Pitas, R. E., Kilbridge, J., Nathan, B., Mahley, R. W., Bu, G., & Schwartz, A. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9480 · Cited by 349
Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis
Mosconi, L., Tsui, W. H., De Santi, S., Li, J., Rusinek, H., Convit, A., Li, Y., Boppana, M., & de Leon, M. J. (2005) · Neurology · doi:10.1212/01.wnl.0000163856.13524.08 · Cited by 336
Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., Schellenberg, G. D., Jin, L.-W., Kovacina, K. S., & Craft, S. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63822-9 · Cited by 331
Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 322
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Self-citationReceptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
The Metabolic Syndrome and Alzheimer Disease
Razay, G., Vreugdenhil, A., & Wilcock, G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.1.93 · Cited by 272
Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E., & Selkoe, D. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63229-4 · Cited by 269
Heneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269
Self-citationKelly, L. J., Vicario, P. P., Thompson, G. M., Candelore, M. R., Doebber, T. W., Ventre, J., Wu, M. S., Meurer, R., Forrest, M. J., Conner, M. W., et al. (1998) · Endocrinology · doi:10.1210/endo.139.12.6384 · Cited by 268
Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M., Purganan, K., Wait, C., Petrova, A., Latendresse, S., Watson, G. S., et al. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00087-2 · Cited by 255
Cerebrospinal Fluid Insulin Levels Increase During Intravenous Insulin Infusions in Man*
WALLUM, B. J., TABORSKY, G. J., PORTE, D., FIGLEWICZ, D. P., JACOBSON, L., BEARD, J. C., WARD, W. K., & DORSA, D. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-190 · Cited by 253
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233
Fagan, A. M., Bu, G., Sun, Y., Daugherty, A., & Holtzman, D. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.47.30121 · Cited by 226
Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
Heaney, A. P., Fernando, M., Yong, W. H., & Melmed, S. (2002) · Nature Medicine · doi:10.1038/nm784 · Cited by 226
PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation
Bernardo, A., & Minghetti, L. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206780574579 · Cited by 220
Eckman, C. B., & Eckman, E. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051101 · Cited by 200
Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance
Andrews, R. C., Herlihy, O., Livingstone, D. E. W., Andrew, R., & Walker, B. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020048 · Cited by 199
CRAFT, S., ASTHANA, S., SCHELLENBERG, G., BAKER, L., CHERRIER, M., BOYT, A. A., MARTINS, R. N., RASKIND, M., PESKIND, E., & PLYMATE, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06371.x · Cited by 191
Rosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain
Strum, J. C., Shehee, R., Virley, D., Richardson, J., Mattie, M., Selley, P., Ghosh, S., Nock, C., Saunders, A., & Roses, A. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11108 · Cited by 183
Hondares, E., Mora, O., Yubero, P., de la Concepción, M. R., Iglesias, R., Giralt, M., & Villarroya, F. (2006) · Endocrinology · doi:10.1210/en.2006-0070 · Cited by 183
Pioglitazone: A Review of its Use in Type 2 Diabetes Mellitus
Waugh, J., Keating, G. M., Plosker, G. L., Easthope, S., & Robinson, D. M. (2006) · Drugs · doi:10.2165/00003495-200666010-00005 · Cited by 180
Shibata, N., Motoi, Y., Tomiyama, H., Ohnuma, T., Kuerban, B., Tomson, K., Komatsu, M., Shimazaki, H., Hattori, N., & Arai, H. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000351419 · Cited by 171
Nathan, B. P., Jiang, Y., Wong, G. K., Shen, F., Brewer, G. J., & Struble, R. G. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03367-4 · Cited by 169
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Camacho, I. E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., & De Strooper, B. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 168
Craft, S. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213866.86934.7e · Cited by 167
Messier, C., & Teutenberg, K. (2005) · Neural Plasticity · doi:10.1155/np.2005.311 · Cited by 167
A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease
FRÖLICH, L., BLUM‐DEGEN, D., RIEDERER, P., & HOYER, S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07839.x · Cited by 160
ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease
Wollmer, M. A., Streffer, J. R., Lütjohann, D., Tsolaki, M., Iakovidou, V., Hegi, T., Pasch, T., Jung, H. H., von Bergmann, K., Nitsch, R. M., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00094-5 · Cited by 158
The Risk of Dementia among Persons with Diabetes Mellitus: A Population‐Based Cohort Studya
Leibson, C. L., Rocca, W. A., Hanson, V., CHA, R., Kokmen, E., O’Brien, P. C., & Palumbo, P. J. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48496.x · Cited by 157
Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., et al. (1999) · Neuroendocrinology · doi:10.1159/000054469 · Cited by 154
Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease
Ambrosi, B., Dall’Asta, C., Cannavò, S., Libé, R., Vigo, T., Epaminonda, P., Chiodini, I., Ferrero, S., Trimarchi, F., Arosio, M., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510173 · Cited by 143
(1997) · PubMed · Cited by 139
Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Allen, T. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000177813.99577.6b · Cited by 126
DeMattos, R. B., Curtiss, L. K., & Williams, D. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.4206 · Cited by 123
Hyperinsulinaemia and Alzheimer's Disease
Razay, G., & Wilcock, G. K. (1994) · Age and Ageing · doi:10.1093/ageing/23.5.396 · Cited by 123
Houten, S. M., & Auwerx, J. H. (2004) · Cell · doi:10.1016/j.cell.2004.09.016 · Cited by 122
PPARγ as a therapeutic target in central nervous system diseases
Sundararajan, S. S., Jiang, Q., Heneka, M. T., & Landreth, G. E. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.020 · Cited by 118
Self-citationRoses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 114
Going nuclear in metabolic and cardiovascular disease
Glass, C. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27913 · Cited by 111
PEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108
Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain
Loane, D. J., Deighan, B. F., Clarke, R. M., Griffin, R. J., Lynch, A. M., & Lynch, M. A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.09.001 · Cited by 94
Farris, W., Leissring, M. A., Hemming, M. L., Chang, A. Y., & Selkoe, D. J. (2005) · Biochemistry · doi:10.1021/bi0476578 · Cited by 91
Brodbeck, J., Balestra, M. E., Saunders, A. M., Roses, A. D., Mahley, R. W., & Huang, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709906104 · Cited by 86
d’Abramo, C., Massone, S., Zingg, J.-M., Pizzuti, A., Marambaud, P., Piccola, B. D., Azzi, A., Marinari, U. M., Pronzato, M. A., & Ricciarelli, R. (2005) · Biochemical Journal · doi:10.1042/bj20050560 · Cited by 81
Hamilton, G., Proitsi, P., Jehu, L., Morgan, A. R., Williams, J. H., O’Donovan, M. C., Owen, M. J., Powell, J. F., & Lovestone, S. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30503 · Cited by 75
Arakawa, R., Hayashi, M., Remaley, A. T., Brewer, B., Yamauchi, Y., & Yokoyama, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300553200 · Cited by 74
A Perspective on Inflammation in Alzheimer's Disease
Rogers, J., & Shen, Y. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05571.x · Cited by 74
Yue, L., Rasouli, N., Ranganathan, G., Kern, P. A., & Mazzone, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408461200 · Cited by 74
Therapeutic Implications of HPA Axis Abnormalities in Alzheimer’s Disease: Review and Update
Pomara, N., Greenberg, W. M., Greenberg, W. M., Doraiswamy, P. M., Branford, M. D., Doraiswamy, A. P. M., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4190 · Cited by 54
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease
Adighibe, O., Arepalli, S., Duckworth, J., Hardy, J., & Vrièze, F. W. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.010 · Cited by 50
Focal Inflammation in the Brain: Role in Alzheimer's Disease
Cooper, N. R., Bradt, B. M., O’Barr, S. A., & Yu, J. X. (2000) · Immunologic Research · doi:10.1385/ir:21:2-3:159 · Cited by 41
Scacchi, R., Pinto, A., Gambina, G., Rosano, A., & Corbo, R. M. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.078 · Cited by 39
Llaverías, G., Rebollo, A., Pou, J., Vázquez‐Carrera, M., Sánchez, R. M., Laguna, J. C., & Alegret, M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.022 · Cited by 39
Piraino, G., Cook, J. A., O’Connor, M. P., Hake, P. W., Burroughs, T. J., Teti, D. V., & Zingarelli, B. (2006) · Shock · doi:10.1097/01.shk.0000223121.03523.69 · Cited by 32
Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone
Morcos, M., Fohr, B., Tafel, J., Pfisterer, F., Hamann, A., Humpert, P. M., Bode, H., Schwenger, V., Zeier, M., Becker, C., et al. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-970162 · Cited by 26
Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease
Leissring, M. A. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025206 · Cited by 19
Panza, F., Capurso, C. A., D’Introno, A., Colacicco, A. M., Vasquez, F., Pistoia, G., Capurso, A., & Solfrizzi, V. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.005 · Cited by 16
Cited by
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410
Metadata
- Authors
- Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 5
- Issue
- 3
- Pages
- 481-489
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2057530150
- Cited by
- 277
- References
- 122
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.